Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Huntington disease
Huntington disease
Huntington disease
Synonyms: Huntington chorea
Synonyms: Huntington chorea
Synonyms: Huntington chorea
Drug discovery
78
drugs
With orphan designations
Rare neurological diseases
Huntington disease
Overview
Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene, leading to progressive motor dysfunction (e.g., chorea, rigidity), cognitive decline, and psychiatric symptoms. Onset typically occurs in mid-adulthood (30–50 years), with juvenile forms (<20 years) presenting severe parkinsonism. Diagnosis is confirmed by genetic testing. While incurable, symptom management includes pharmacotherapy, multidisciplinary care, and emerging disease-modifying therapies targeting mutant huntingtin protein (mHTT) reduction [1][5][9][13].
Burden
Life expectancy: 10–30 years post-onset; juvenile HD progresses faster [9][13].
High morbidity: Loss of independence, dysphagia, dementia, and suicide rates 4–8× higher than general population [9][13][16].
Economic/psychosocial strain: Full-time care required in advanced stages; significant caregiver burden [17][20].
Therapies
Symptomatic control: Chorea managed with VMAT2 inhibitors (tetrabenazine, deutetrabenazine), antipsychotics (olanzapine), and anti-glutamatergics (amantadine, riluzole) [3][9][19].
Supportive care: Physical/occupational therapy, psychiatric interventions, and caregiver support [1][17].
Emerging therapies: Antisense oligonucleotides (ASOs, e.g., RG6042 in Phase 3), RNA interference, and CRISPR-based gene editing to reduce mHTT [7][11][15].
Categories: rare genetic diseases, rare neurological diseases, rare ophthalmic disorders
Research Papers
5,212 drug discovery papers about Huntington disease, with 2 first-in-class and 73 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
5,212 drug discovery papers about Huntington disease, with 2 first-in-class and 73 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
categories:
Small molecules
small molecules
2026-09-30 | Estrogen and progesterone receptor signaling as candidate neuroendocrine modulators in Huntington's disease.
Huntington's disease (HD) is a genetically driven neurodegenerative disorder marked by progressive corticostriatal dysfunction, excitotoxicity, mitochondrial impairment, and neuroinflammation. Disease-modifying therapies remain limited, and the receptor-specific relevance of neuroendocrine signaling is poorly defined.This review evaluates estrogen receptor beta (ERβ), G-protein-coupled estrogen receptor 1 (GPER1), and progesterone-derived neurosteroids, particularly allopregnanolone, as candidate modulators of HD vulnerability. A structured search of PubMed, Web of Science, and Scopus covered studies published from January 1, 1990, through October 1, 2025, supplemented by manual reference screening. Evidence from patients and HD models is prioritized; mechanistic findings from other neurodegenerative and excitotoxic models are interpreted cautiously.We examine receptor-specific effects on glutamatergic signaling, mitochondrial bioenergetics, microglial activation, oxidative stress, and transcription, including potential disruption of estrogen-responsive pathways by mutant huntingtin. Sex differences, hypothalamic-pituitary-gonadal axis disturbances, and neurosteroid fluctuations are also considered.Finally, we assess SERMs, ERβ-selective agonists, and progesterone-based strategies as hypothesis-driven adjuncts-not established treatments-while addressing thromboembolic risk, endocrine contraindications, CNS penetration, receptor selectivity, and drug interactions. This synthesis identifies evidence gaps and proposes testable questions for early-phase translational research.
2026-09-30 | Lipid-based Nanocarriers for Neurodegenerative Disorders: Bridging Blood-brain Barrier Biology and Translational Drug Delivery.
Neurodegenerative disorders, including Alzheimer's, Parkinson's, Huntington's disease, and amyotrophic lateral sclerosis, remain difficult to treat because the Blood-brain Barrier (BBB) severely restricts therapeutic access to the central nervous system. This review evaluates BBB biology and the potential of lipid-based nanocarriers to improve brain-targeted drug delivery and facilitate clinical translation. A structured narrative review of peer-reviewed preclinical and clinical literature published between 2000 and 2025 was conducted using PubMed, Scopus, and Web of Science. Evidence concerning BBB structure and transport mechanisms, lipid-based nanocarrier design, physicochemical characteristics, drug-release behavior, computational modelling, therapeutic applications, and translational challenges was critically synthesized. Liposomes, nanoemulsions, solid lipid nanoparticles, nanostructured lipid carriers, and lipid-polymer hybrid nanoparticles demonstrated improved drug solubility, stability, controlled release, systemic circulation, and brain targeting. Preclinical evidence indicates enhanced brain bioavailability and therapeutic effects, including reductions in neuroinflammation, oxidative stress, and disease-associated pathological processes. However, clinical translation remains constrained by formulation complexity, scalability, long-term safety, and inconsistent clinical outcomes. Integration of BBB transport biology with surface functionalization, receptormediated targeting, formulation engineering, and computational modelling may enable more rational nanocarrier development. Nevertheless, standardized characterization, reproducible manufacturing, comprehensive safety evaluation, and stronger clinical validation are required to bridge the gap between promising preclinical findings and therapeutic implementation. Lipid-based nanocarriers represent promising platforms for overcoming biological and pharmacokinetic barriers in neurodegenerative disorders. Further optimization and rigorous translational validation are essential to establish their safety, reproducibility, and clinical effectiveness.
2026-09-27 | Uncovering hidden protein networks in Huntington's disease: implications for pathogenesis and therapy.
Huntington's Disease is a neurodegenerative disorder that progresses over time and can be passed down from parent to child. In uncontrolled motor activities, behavioural problems come into play, as well as progressive mental decline. The CAG triplet in the HTT gene found on chromosome 4 undergoes changes, leading to the production of a mutant protein called huntingtin, which consists of a bigger-than-normal polyglutamine tract that then undergoes misfolding and produces toxic oligomers and fibrillar deposits that can cause dysfunction in normal cell functioning and therefore in nerve cells as well. Although early research linked the pathophysiology of Huntington's disease primarily to mHTT aggregation, more recent research indicates broad protein-protein interaction networks that affect several cellular pathways. Systems biology approaches using tools such as STRING, BioGRID, and Cytoscape have provided evidence of interconnected networks that promote proteostasis, mitochondrial dynamics, energy metabolism, neuroinflammation, synaptic transmission, and transcriptional and epigenetic regulation. Important protein hubs, including HSP70, DRP1, NLRP3, and TFEB, act as central controls that bind those pathways. mHTT-mediated defect in the function of the ubiquitin-proteasome system promotes mitochondrial oxidative stress, which triggers the NLRP3 inflammasome, leading to synaptic dysfunction and specific loss of striatal medium spiny neurons. Investigations using various experimental techniques, which involve R6/2 and YAC128 mouse models, neurons derived from human iPS cells, and multi-omics studies, reveal that faulty neuroplasticity develops before the formation of visible protein aggregates. As for therapeutics targeting central components of neuronal networks, they have all demonstrated certain neuroprotective effects.
2026-09-25 | Restoring Aquaporin-4 alleviates molecular and motor phenotypes in zQ175 mouse model of Huntington disease
Huntington&'s disease (HD) is characterized by progressive accumulation of mutant huntingtin (mHTT), neurodegeneration and motor dysfunction. Increasing evidence implicates impaired glymphatic function and loss of perivascular aquaporin 4 (AQP4) polarization in HD, suggesting that defective brain waste clearance may contribute to disease pathogenesis. Whether restoration of AQP4&-mediated glymphatic transport can ameliorate HD pathology remains unknown. We tested whether genetic restoration of AQP4 improves glymphatic function and HD&-associated phenotypes in heterozygous zQ175 knock-in mice. At 2 months of age, premanifest zQ175 mice received a single retro-orbital injection of BBB-penetrant AAV9&-PHP.eB encoding the AQP4 (M1 isoform). Glymphatic transport was assessed by intracisternal injection of fluorescent BSA 647 and quantification of parenchymal influx and drainage to the deep cervical lymph nodes. Perivascular AQP4 localization, mHTT aggregation, gliosis, DARPP32 immunoreactivity, CSF neurofilament light chain (NfL) and total Tau, structural brain volumes by 11.7T MRI, and motor behavior were assessed longitudinally through 12 months of age. AAV9&-PHP.eB&-AQP4 produced widespread brain expression and restored perivascular AQP4 localization in the striatum and cortex of zQ175 mice. AQP4 overexpression significantly increased glymphatic tracer influx into brain parenchyma and BSA-647 drainage to the deep cervical lymph nodes. At 12 months, AQP4 restoration reduced CSF NfL and total Tau concentrations, mHTT aggregate number and mean aggregate size, and striatal Iba1 positive microglia and GFAP-positive astrocytes (P < 0.05). AQP4 overexpression also preserved striatal DARPP32 immunoreactivity and significantly attenuated striatal atrophy measured by MRI. Female zQ175 mice showed improved balance-beam performance and locomotor activity, while effects on motor performance in males did not reach statistical significance. AQP4 overexpression attenuated body-weight loss in both sexes. No detectable structural, behavioral or body-weight abnormalities were observed following sustained AQP4 overexpression in wild-type mice. In summary, restoration of AQP4 enhances glymphatic transport and is associated with reduced proteopathic, neuroinflammatory and neurodegenerative phenotypes in zQ175 HD mice. These findings provide proof-of-concept that impaired glymphatic function is a modifiable component of HD pathology and support AQP4&-mediated restoration of brain waste clearance pathways as a potential disease-modifying therapeutic strategy.
2026-09-25 | miR-196a reduces mutant Huntingtin aggregates by Rad23b-mediated degradation in Huntington's disease.
Huntington's disease (HD) is a neurodegenerative disorder caused by abnormal expansions of poly-glutamine repeats in the mutant Huntingtin (mHTT). The expanded proteins form pathological aggregates to disrupt neuronal functions during disease progression, suggesting the clearance of the aggregates is considered as a potential direction for development of therapy. Our previous studies have demonstrated one specific microRNA, miR-196a, downregulates mHTT aggregates and improves the pathological phenotypes in HD. However, the detailed mechanism remains unclear. Proteomic analyses and bioinformatic tools were used to identify putative miR-196a targets in HD, and the expression of one target gene, Rad23b, was manipulated in different HD models to assess its role in mHTT aggregates. Here, we identify Rad23b as a key target, and miR-196a directly downregulates Rad23b to reduce mHTT aggregates and toxicity. We also show Rad23b overexpression worsens mHTT pathology, while its knockdown or knockout diminishes aggregates, primarily through the ubiquitin-proteasome system (UPS). Moreover, Rad23b interacts with mHTT aggregates via its ubiquitin-binding domains, and promotes their ubiquitination; however, Rad23b disrupts the chymotrypsin-like activity of UPS, and contributes to mHTT accumulation. In transgenic mouse models in vivo, Rad23b increases mHTT aggregates and cell death in brains, and also worsens motor dysfunction in HD transgenic mice. These findings demonstrate that critical role of Rad23b in miR-196a-reduced pathological aggregates, and highly suggest downregulating Rad23b or disrupting its interaction with mHTT may offer novel strategies to mitigate mHTT aggregates to delay disease progression.
cell therapies
2026-09-04 | Extracellular vesicles in neurodegenerative diseases: A new frontier in diagnosis and therapy.
Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease are among the progressive disorders of the nervous system that are characterized by the gradual destruction of neurons, the accumulation of misfolded proteins, and the limited effective therapeutic options. In recent years, numerous lines of evidence have emphasized the important role of extracellular vesicles (EVs) in the formation and progression of these diseases. These vesicles are membrane-bound nanoscale structures that are secreted by almost all cell types and play a role in cell-cell communication through the transfer of molecules such as proteins, lipids, and nucleic acids. In neurodegenerative disorders, EVs can facilitate the transport and dissemination of disease-related proteins, including amyloid-β, tau, α-synuclein, mutant huntingtin, SOD1, and TDP-43, thus contributing to the spread of pathological processes in different parts of the nervous system. On the other hand, the ability of these vesicles to cross the blood-brain barrier and reflect molecular changes occurring in the central nervous system makes them valuable candidates for the development of minimally invasive biomarkers. This review reviews the biogenesis, classification, isolation methods, and molecular content of EVs, and analyzes their role in the pathogenesis, diagnosis, and treatment of the most important neurodegenerative diseases. Also, the importance of EV-associated proteins, RNAs, and lipids as emerging diagnostic biomarkers, as well as the therapeutic potential of natural and engineered vesicles as drug delivery systems and regulators of neuroinflammation and neurodegenerative processes, is discussed.
2026-08-29 | Mechanism and progress of deep brain stimulation in the treatment of neurological and psychiatric disorders.
Deep brain stimulation (DBS) is a reversible and adjustable neurostimulation technique, and has been established as a significant therapeutic modality in functional neurosurgery although its mechanisms are not yet fully understood. The primary indications for DBS include movement disorders such as Parkinson's disease (PD) and dystonia, essential tremor (ET), and Huntington's disease (HD). In recent years, its application has expanded to encompass the treatment of various other neurological and psychiatric conditions, including epilepsy, depression, obsessive-compulsive disorder (OCD), Alzheimer's disease (AD), and Tourette syndrome (TS), although the indications for DBS currently approved by the Food and Drug Administration (FDA) are PD, dystonia, ET, OCD, and epilepsy. In this review, we summarize the prevailing hypotheses regarding the mechanisms through which DBS ameliorates neurological and psychiatric disorders. We also describe the advancements in DBS for treating PD, dystonia, epilepsy, and other brain disorders. Furthermore, we outline the limitations associated with DBS treatment to date. Through this comprehensive analysis, we aim to enhance the understanding of DBS applications in neurological and psychiatric diseases and suggest potential avenues for technological advancement.
2026-08-08 | Gelatin methacryloyl hydrogel as a potential scaffold for cell transplantation for Huntington's disease.
Cell replacement therapy is a promising strategy for treating Huntington's disease. Advances in cell reprogramming now allow the generation of clinically relevant cells; however, conventional delivery methods can compromise long-term cell survival and maturation. Hydrogels have emerged as supportive three-dimensional scaffolds that better mimic the in vivo environment. This study examined whether encapsulating human-induced lateral ganglionic eminence precursor cells (hiLGEPs) in gelatin methacryloyl (GelMA) hydrogel enhanced differentiation after transplantation into the striatum of the quinolinic acid lesion rat model of Huntington's disease. hiLGEPs were delivered either in cell culture medium (n = 5) or in a pre-crosslinked GelMA solution (n = 4) prior to transplantation. GelMA was polymerized in situ using a visible-light optical fibre system, and grafts were assessed 4 weeks later. Transplanted cells survived in all animals. Notably, GelMA-encapsulated hiLGEPs produced significantly more protein gene product 9.5 (PGP9.5+) neurons than those delivered in cell culture medium. Transplanted cells in both groups differentiated into microtubule-associated protein 2 (MAP2+) and GABA+ phenotypes, with no detectable differences in graft volume. These findings provide the first evidence that encapsulating hiLGEPs in GelMA enhances early neuronal differentiation following transplantation, supporting GelMA hydrogel as a promising delivery scaffold for cell replacement therapy in Huntington's disease.
2026-06-26 | Oxidative stress and molecular chaperones: a dynamic crosstalk in neurodegenerative disorders.
Neurodegenerative diseases (NDs), such as Alzheimer's disease, Parkinson's disease, and Huntington's disease are discussed as representative examples of conditions in which oxidative stress and proteostasis imbalance contribute to progressive neuronal dysfunction. Oxidative stress, defined as an imbalance between reactive oxygen species (ROS) production and antioxidant defenses, is widely recognized as a key contributor to ND pathogenesis. Excessive ROS disrupt cellular homeostasis and promotes protein misfolding and aggregation, thereby compromising the proteostasis network. In response to this stress, molecular chaperones, including members of heat shock protein (Hsp) family, play a crucial protective role by maintaining protein folding integrity and preventing toxic aggregation. Furthermore, mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) serve as carriers of bioactive molecules, including antioxidants and molecular chaperones, offering a unique mechanism to restore cellular homeostasis. This review explores the interplay between oxidative stress and molecular chaperones in the pathogenesis of NDs and highlights the emerging therapeutic potential of MSC-EVs as modulators of oxidative and proteostatic imbalance.
2026-06-18 | Sequential Clinical Changes Following Autologous Mesenchymal Stem Cell Therapy in a Patient With Concurrent Huntington's Disease and Ankylosing Spondylitis: A Case Report.
Huntington's disease (HD) and ankylosing spondylitis (AS) are genetically and pathophysiologically distinct conditions, and their concurrent management may present a complex clinical challenge. A case is reported of a 35-year-old man with genetically confirmed HD and concurrently diagnosed AS, treated with autologous mesenchymal stem cell (MSC) therapy over three consecutive monthly sessions (50 million MSCs per session, total 150 million administered, intravenous and epidural routes). Validated disease-specific assessments were performed at each visit by the treating neurologist before the cell administration of that day: the Unified Huntington's Disease Rating Scale motor score (UHDRS motor), the Bath Ankylosing Spondylitis Functional Index (BASFI), and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Three serial assessments captured changes from baseline (cumulative dose 0) through cumulative doses of 50 million and 100 million MSCs, after which the third (final) dose was administered without subsequent reassessment. Over the two-month observation period, UHDRS motor score declined from 19 to 2, BASFI from 4.0 to 1.0 (with a transient increase to 8.5 at the second visit), and BASDAI from 2.0 to 1.0. No serious short-term adverse events were observed during the active treatment period. Given the single-patient design, concurrent pharmacotherapy, unblinded assessment, absence of objective biomarkers, and absence of post-third-dose assessment, causal attribution to MSC therapy cannot be established. The observation is presented as hypothesis-generating and warrants further investigation under controlled conditions.
proteins
2026-09-28 | Masking phosphatidylserine prevents neuronal loss in two distinct Drosophila models of neurodegeneration.
Neuronal loss is a hallmark of neurodegenerative diseases. Phosphatidylserine (PS), a key "eat me" signal, is exposed on stressed viable neurons, triggering their premature phagocytosis by activated glia. We investigated whether PS masking could serve as a universal strategy to prevent neuronal loss in two distinct Drosophila models of neurodegeneration: an adult-stage-specific knockdown of skpA and a Huntington's disease model initiated during embryogenesis. Both models exhibit neuronal loss, motor dysfunction, and reduced lifespan. To mask PS, we used a truncated form of Milk Fat Globule-Epidermal Growth Factor 8, a glycoprotein that binds PS without promoting engulfment. PS masking preserved two neuronal populations in both models, indicating that these neurons were eliminated alive via phagoptosis. Motor function and lifespan were improved to varying degrees, depending on the timing and severity of neuronal damage. These findings reveal that aberrant glial phagocytosis contributes to neuronal vulnerability and identify PS masking as a promising therapeutic approach for neurodegenerative diseases.
2026-09-24 | Protecting Against Cytoplasmic Protein Aggregates With Cytoplasmic PML Variants.
Cytoplasmic protein aggregation is a defining feature of multiple neurodegenerative diseases, including amyotrophic lateral sclerosis, frontotemporal dementia, Huntington's disease, and certain forms of motor neuron disease. Recent evidence indicates that promyelocytic leukemia protein (PML) and engineered PML-derived variants can act as versatile aggregate-remodeling factors. In particular, cytoplasmically redirected PML variants recognize pathological cytoplasmic inclusions and promote their clearance. Here, we describe a protocol to generate and validate two engineered cytoplasmic PML variants: full-length mPML, which is redirected to the cytoplasm by disruption of its nuclear localization sequence, and the truncated mPMLΔRBC variant, which lacks the RING, B-box, and coiled-coil domain but retains aggregate-reducing activity. The protocol integrates fluorescence-based imaging, bimolecular fluorescence complementation, detergent-soluble/insoluble fractionation, and validation in primary rat cortical neurons. This workflow provides a practical platform for assessing cytoplasmic aggregate burden and for comparing the aggregate-remodeling activities of PML-derived constructs. It can also be adapted to other disease-associated aggregation-prone proteins, including TDP-43, SOD1, FUS, tau, polyGA, and polyQ-expanded proteins. Key features • Describes the generation and validation of two complementary cytoplasmic PML variants: full-length mPML and truncated mPMLΔRBC. • Provides fluorescence-based and BiFC-based assays to visualize pathological cytoplasmic protein assemblies. • Includes detergent-soluble/insoluble fractionation for biochemical assessment of aggregate burden. • Establishes a primary rat cortical neuron workflow to evaluate the effect of mPML on TDP-43-CTF aggregates. • Can be adapted to other aggregation-prone proteins and additional PML-derived aggregate-remodeling candidates.
2026-09-04 | Targeting Klotho Signaling for Neuroprotection in Huntington's Disease: A Comprehensive Review.
HD is a hereditary neurodegenerative disease caused by the amplification of the CAG trinucleotide repeat in the HTT gene, leading to a Mutant Huntingtin (mHTT) protein that dysregulates transcription, promotes protein aggregation, induces neuroinflammation, and impairs mitochondrial function. Motor dysfunction, cognitive decline, and mental disorders are manifestations of these biochemical abnormalities. Effective disease-modifying treatments are still limited, even with recent improvements. This review investigates the increasing relevance of Klotho, an anti-aging protein with neuroprotective, antioxidant, and anti-inflammatory characteristics, as a possible therapeutic target in Huntington disease. We did a comprehensive literature search across PubMed, Scopus, and Web of Science databases. Klotho's molecular functions in neural protection, energy metabolism, oxidative stress reduction, and anti-inflammatory signalling were investigated in the context of HD pathogenesis. Klotho appears to influence critical neurodegenerative processes involved in HD. It inhibits NF-κB and NLRP3 inflammasome activity, stimulates antioxidant enzyme expression (SOD, catalase), promotes GluN2B-NMDA receptor-mediated synaptic plasticity, and increases astrocytic aerobic glycolysis via FGFR1-ERK signaling. These functions may mitigate mHTT- induced neuronal damage. Pharmacologic treatments (e.g., PPAR-γ agonists), vitamin D, and lifestyle interventions can all modulate klotho expression. Klotho exhibits neuroprotective effects in Huntington's disease by reducing NF-κB/NLRP3- mediated inflammation, strengthening antioxidant defenses, promoting GluN2B-NMDA- dependent synaptic plasticity, and improving astrocytic metabolic support via FGFR1-ERK signaling. One intriguing treatment approach for mutant huntingtin-induced neurotoxicity is the modification of klotho expression. Klotho is a promising neurochemical modulator with disease-modifying properties in HD. Its multifunctional protective activities are consistent with important pathological markers of HD, necessitating more preclinical and clinical studies to confirm its translational value.
2026-08-11 | A Novel Plate Reader-Based Protocol for Measurement of DNAJB6 Dimerization Activity.
Progressive neurodegeneration linked to the accumulation of misfolded proteins is a hallmark of several neurodegenerative disorders, including Parkinson's disease, Huntington's disease, and Alzheimer's disease. Dysfunction in the protein homeostasis machinery correlates with pathology. The chaperone protein DNAJB6 is expressed in neurons and oligodendrocytes and has been shown to play a key role in preventing amyloid aggregation by binding to amyloidogenic proteins and facilitating their refolding or degradation, in cooperation with other chaperones. Here, we describe a simple and feasible assay that enables high-throughput screening for DNAJB6 activity in a plate reader format. We use genetically engineered HEK293 cells that stably express DNAJB6 fused to either CFP or YFP. These cells can be plated into multi-well plates, and the fluorescence resonance energy transfer (FRET) signal can be measured for analysis of DNAJB6 dimerization, which is linked to DNAJB6 activity. The protocol can be used for drug screening and to identify compounds that increase DNAJB6 dimerization, and can serve as a starting point for finding new medicines that act through modulating DNAJB6 activity. Key features • The protocol requires a plate reader capable of FRET analysis and bandwidth adjustment for CFP/YFP separation. It was developed using a CLARIOstar plate reader. • The protocol requires access to the authors' FRET DNAJB6 cell line or equivalent cells with stable expression of CFP/YFP-DNAJB6. • The assay measures DNAJB6 dimerization and can potentially be adapted to other proteins whose functional state is linked to dimerization activity. • The protocol is useful for compound screening purposes and requires pre-existing knowledge of basic cell culture.
2026-08-05 | Targeting mitochondria for the treatment of neurodegenerative diseases.
Mitochondria are central regulators of cellular metabolism, redox balance, calcium signaling, and cell survival, making them essential for neuronal function. Because neurons rely heavily on mitochondrial oxidative phosphorylation to meet their high energetic demands, mitochondrial dysfunction has emerged as a key pathogenic driver in major neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Defects in mitochondrial bioenergetics, excessive reactive oxygen species production, impaired mitochondrial dynamics, disrupted mitophagy, and dysregulated calcium handling collectively contribute to neuronal damage, synaptic dysfunction, and neuroinflammation. These insights have prompted growing interest in therapeutic strategies that directly target mitochondria to restore organelle homeostasis. Recent advances in chemical biology and nanomedicine have enabled the development of mitochondria-targeted ligands, peptide-based targeting systems, and carrier or nanotechnology-enabled delivery platforms designed to overcome biological barriers and selectively deliver therapeutic cargos to mitochondria within the central nervous system. In this Review, we summarize mitochondrial pathological mechanisms in neurodegenerative diseases and discuss emerging mitochondria-targeted therapeutic strategies, highlighting delivery technologies, therapeutic modalities, and translational challenges. Although most strategies remain at the preclinical or proof-of-principle stage, these advances are beginning to shape a conceptual framework for precision mitochondrial medicine, with the longer-term goal of developing disease-modifying interventions for neurodegenerative disorders.
oligonucleotides
2026-09-05 | New directions in diagnosis and therapeutic for Huntington disease
Physical sign, behavioral, as well as increasing cognition are hallmarks of Huntington Disease (HD), a monogenic neurodegenerative illness that causes early impairment and death. In 1993, the genetic effect was identified as an enlarged Cytosine, Adenine, Guanine repeat on chromosome 4's exon 1 of the Huntington gene. The assessment of individuals who are clinically afflicted by Huntington's disease depends on the differential diagnosis. A variety of treatments are accessible to lessen the symptoms of Hunti ngton's disorder, and efficient solutions for its chorea. Additionally, RNA interference medicines are being developed for clinical use, antibody treatments, stem cell treatments, etc. Discussing the effectiveness of the recent therapy for Huntington's illness is the main ambition in this regard comprehen sive analysis.
2026-08-12 | Blocking somatic repeat expansion and lowering huntingtin by RNAi synergize to attenuate Huntington's disease pathogenesis in mice.
Huntington's disease (HD) is a progressive neurodegenerative disorder with no approved therapies. Despite multiple clinical trials, huntingtin (HTT)-lowering strategies have yet to show meaningful clinical benefit. Both somatic expansion and toxic HTT species are key molecular drivers of HD, yet therapeutic strategies targeting these pathways have never been directly compared or evaluated in combination. Using therapeutic divalent siRNAs, we assessed the long-term impact of silencing MutS homolog 3 (MSH3), a critical regulator of somatic expansion, HTT, or both in Q111 HD mice (>110 CAGs), which develop robust expansion, mutant HTT inclusions, and transcriptional dysregulation by 12 months. Long-term MSH3 silencing blocked somatic expansion, reduced inclusions, and normalized gene expression. HTT silencing alone had a limited effect, whereas combined MSH3/HTT targeting synergistically eliminated inclusions and restored transcriptomic profiles. Parallel treatment in wild-type mice showed no toxicity, supporting the safety of long-term intervention. These findings position somatic expansion as a promising therapeutic target and demonstrate the potential of RNAi-based cosilencing of MSH3 and HTT as a disease-modifying strategy for HD.
2026-08-11 | Emerging Pharmacological Therapies for Huntington's Disease: Translational Insights from Recent Clinical Trials.
Huntington's disease [HD] is a progressive, autosomal dominant neurodegenerative disorder caused by a pathogenic CAG repeat expansion in the HTT gene, resulting in mutant huntingtin [mHTT] protein accumulation, neuronal dysfunction, and selective neurodegeneration. Current pharmacological management remains largely symptomatic, with no approved therapies capable of modifying disease progression. In recent years, however, significant advances in molecular neuroscience and translational medicine have accelerated the development of disease-modifying strategies targeting the underlying pathogenic mechanisms of HD. This review synthesizes emerging pharmacological therapies with a particular focus on insights derived from recent and ongoing clinical trials. Key therapeutic approaches discussed include gene-silencing technologies such as antisense oligonucleotides, RNA interference, and CRISPRCas9- based strategies, as well as small-molecule modulators targeting mutant huntingtin aggregation, proteostasis, autophagy, mitochondrial dysfunction, and neuroinflammation. In addition, advances in symptomatic treatments addressing motor, cognitive, and psychiatric manifestations are reviewed. The article critically examines translational challenges encountered in clinical development, including blood-brain barrier penetration, allele selectivity, dosing paradigms, patient heterogeneity, biomarker integration, and ethical considerations associated with irreversible genetic interventions. Lessons learned from both successful and failed trials highlight the importance of precision medicine approaches, biomarker-guided trial designs, and combination therapies targeting multiple pathogenic pathways. Collectively, this review provides an updated and clinically relevant overview of the evolving HD therapeutic landscape and outlines key considerations for translating molecular advances into effective and safe pharmacological interventions.
2026-07-08 | Huntington's disease in the era of somatic instability, biomarkers, and targeted therapies: A narrative review.
Huntington's disease (HD) is a progressive, autosomal dominant neurodegenerative disorder caused by cytosine-adenine-guanine (CAG) trinucleotide repeat expansion in the huntingtin gene (HTT), resulting in mutant huntingtin (mHTT) with toxic gain-of-function and partial loss of normal huntingtin function. This narrative review summarizes recent advances in genetics, pathophysiology, clinical features, diagnostic assessment, biomarkers, and therapeutic development. Genetic testing demonstrating an expanded HTT CAG repeat is the definitive diagnostic test and should be interpreted with genetic counseling and attention to allele categories. Pathophysiologically, HD involves CAG instability, age-dependent somatic expansion in vulnerable neurons, transcriptional dysregulation, proteostasis failure, mitochondrial dysfunction, excitotoxicity, and neuroinflammation, leading primarily to degeneration of striatal medium spiny neurons and later cortical involvement. Clinically, HD can begin from juvenile to late-adult life and manifests with motor, cognitive, psychiatric, and behavioral symptoms that evolve from premanifest biological change to functional decline. Current clinical care relies on symptom-directed treatment, whereas quantitative neuroimaging, cerebrospinal fluid biomarkers are mainly used for research and trial enrichment. Symptomatic management includes vesicular monoamine transporter type 2 inhibitors, antipsychotics, rehabilitation, nutritional support, and multidisciplinary care. Emerging disease-modifying approaches include HTT-lowering, somatic expansion inhibition, and gene-based therapies, but efficacy depends on target selectivity, timing, delivery route, dose, and patient selection.
2026-07-03 | Mismatch repair dissection by in vivo RNAi reveals dose-dependent modulators of somatic instability and proteome remodeling in Huntington's disease.
Human and mouse genetics have established mismatch repair (MMR) as a central mediator of somatic repeat expansion, a key pathogenic process in Huntington's disease (HD) and related disorders. How individual MMR components function within the intact mammalian brain and interact with broader cellular networks remains poorly understood. We screened more than 500 chemically stabilized siRNAs targeting 10 MMR genes and used interventional RNAi in the Q111 HD mouse model to systematically dissect MMR function in vivo. MSH3 and PMS1 emerged as the most dose-sensitive regulators of somatic expansion but displayed markedly different effects on proteome stability. Quantitative proteomics generated an in vivo atlas of MMR component abundance and cross-regulation in the mammalian CNS, uncovering extensive connectivity between DNA repair, transcriptional regulation, chromatin remodeling, and mitochondrial biology. Together, these findings establish a systems-level framework linking MMR biology to neuronal function and offer mechanistic insight into selective neuronal vulnerability in HD.
other
2026-09-27 | Huntingtin Aggregate-Responsive Autophagy Gene Circuit Mitigates Disease Pathology in R6/2 Mice.
The accumulation of mutant huntingtin (mHTT) aggregates drives the pathology of Huntington's disease (HD), yet therapies capable of distinguishing toxic species from wild-type proteins remain elusive. Here, a synthetic gene circuit, termed ARAA, was engineered to couple the preferential recognition of aggregated polyQ species to the on-demand activation of autophagy. Utilizing a repurposed bacterial NarX-NarL system fused with a conformation-sensitive intrabody, the circuit detects pathological polyQ conformers and triggers the transcriptional expression of the master autophagy regulator TFEB. To enable systemic application, the ARAA plasmid is encapsulated in CD98-targeted immunoliposomes (LIP-CD98) that facilitate efficient blood-brain barrier crossing via receptor-mediated transcytosis. In the R6/2 HD mouse model, ARAA treatment significantly reduces mHTT burden, attenuates neuroinflammation, and rescues synaptic deficits. This closed-loop intervention improves motor function and extends lifespan. Together, these findings provide proof-of-concept evidence that aggregate-responsive regulation of autophagy can mitigate disease-associated phenotypes in exon 1-based HD models.
2026-09-24 | Chemically modified CRISPR enzymes for multi-organ genome editing in vivo.
Delivery remains the main obstacle to the development of in vivo genome editing therapies. CRISPR ribonucleoproteins confer high editing activity with transient exposure but lack intrinsic cell entry and targeting. Here we introduce PERCEPT, a delivery platform featuring reversible, covalent modification of CRISPR enzymes. PERCEPT enables modular installation of shielding polymers, amphiphilic delivery peptides and targeting ligands, allowing traceless cytosolic release of the native editor. A formulation incorporating an amphiphilic delivery peptide and the neuron-targeting ligand TET1 edited approximately 56% of striatal volume and 78% of neurons within edited regions after local striatal administration. In the R6/2 Huntington's disease model, PERCEPT mediated targeted editing of the mutant human HTT transgene, reducing mutant huntingtin aggregate burden and shifting local transcriptional programs away from inflammatory and injury-associated states. Tissue-adapted formulations edited 53% of Müller glia following intravitreal delivery, increased skeletal muscle reporter fluorescence tenfold versus unconjugated control following intramuscular injection, and enabled lung airway epithelial cell that persisted for three months following intranasal delivery. Rapid screening revealed that local anatomical and cellular barriers require distinct surface display for optimal editing. These results establish reversible chemical modification as a general strategy for adapting CRISPR enzyme delivery across multiple target tissues in vivo.
2026-08-23 | Comparative Analysis of CRISPR-Cas9 and Gene-Lowering Approaches for the Treatment of Huntington’s Disease
Huntington's disease is a severe autosomal dominant inherited disease, which means a person will suffer from this disease even if only one allele is mutated.The disease is caused by CAG trinucleotide repeat expansion in 4th chromosome, HTT gene, and only a little approach could be helpful to treat this disease from now.Today, approximately 5 out of every 100,000 people will suffer from this disease all around the world.This article explores two groundbreaking technologies that emerged at the end of 2025, marking the first time Huntington's disease has ever been successfully treated.Two rivaling approaches are at play: CRISPR-Cas9 editing of the gene responsible for Huntington's disease (HTT), and gene-lowering, which involves the degradation of the mRNA produced by miRNA.In previous research, the gene-lowering method functioned in mutant Huntington mRNA, instead of targeting the gene itself.This paper compares the benefits and shortcomings of these two prevailing methods for curing Huntington's disease.According to this paper, the gene-lowering method is relatively mature, and it is getting increasingly closer to being released in the market as a drug.The CRISPR-Cas 9 method is theoretically more efficient due to its once-and-for-all characteristic, and could be more convenient.However, both treatments are all facing the delivery challenge.This paper provides a comprehensive comparison of two novel approaches for treating Huntington's disease, providing a roadmap for where this research needs improvement, and may progress in the future.
2026-08-04 | Enhancing the detection of HTT1a with neoepitope antibodies in mouse models of Huntington's disease.
Huntington's disease is an inherited neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of the huntingtin (HTT) gene, encoding an expanded polyglutamine tract in the huntingtin (HTT) protein. The pathogenic CAG repeat of HTT is unstable and undergoes progressive somatic expansion in specific brain cells and peripheral tissues throughout life. Genes involved in DNA mismatch repair pathways, which promote repeat expansion, have been identified as genetic modifiers of the disease. Consequently, the rate of CAG repeat expansion is a key determinant driving the age of onset and disease progression. As the CAG repeat expands, alternative processing of HTT pre-mRNA increasingly favours production of the HTT1a transcript, which encodes the highly pathogenic and aggregation-prone HTT1a protein. This process provides a mechanistic link between CAG repeat expansion and disease pathogenesis, as increased HTT1a production accelerates HTT aggregation and neuronal dysfunction. HTT1a has previously been detected in Huntington's disease mouse models by using immunoprecipitation coupled with western blotting, homogeneous time-resolved fluorescence (HTRF) and Meso Scale Discovery (MSD) bioassays and immunohistochemistry. These approaches were developed using MW8, a neoepitope antibody that specifically recognizes the C-terminus of HTT1a. MW8 is a relatively weak antibody with limited detection sensitivity. To generate more robust HTT1a-specific reagents, two novel recombinant antibodies, 1B12 and 11G2, have been developed for evaluation. Using an allelic series of knock-in (HdhQ20, HdhQ50, HdhQ80, HdhQ111, CAG140 and zQ175) mice, alongside transgenic YAC128 and N171-82Q models, we extensively evaluated and compared the performance of MW8, 1B12 and 11G2. We demonstrate that 1B12 and 11G2 function as HTT1a-specific neoepitope antibodies by immunoprecipitation with western blotting and by immunohistochemistry. To enhance HTT1a detection using HTRF and MSD technology platforms, we further evaluated the performance of 1B12 and 11G2 in HTT bioassays using cortical lysates from zQ175 and YAC128 mice. In zQ175 mice, enhanced detection of aggregated HTT1a by HTRF and MSD revealed that HTT fragments longer than HTT1a can be incorporated into HTT1a-containing aggregates. The most sensitive assays were subsequently applied across the allelic series of knock-in mice to assess the effect of polyglutamine length on bioassay performance. For optimal sensitivity, we recommend the preferential use of 1B12 for HTRF assays and 11G2 for MSD assays. Collectively, these findings establish 1B12 and 11G2 as robust antibodies to reliably detect and track HTT1a pathology in vivo and promote the replacement of previously used MW8-based experimental approaches.
2026-07-30 | In vivo CRISPR base editing for treatment of Huntington's disease.
Huntington's disease (HD) is a fatal neurodegenerative disorder caused by an expanded CAG repeat within exon 1 of the huntingtin (HTT) gene, resulting in a mutant protein that drives neuronal dysfunction and loss. A key event in the pathogenesis of HD is proteolytic cleavage of mutant HTT, which generates aggregation-prone N-terminal fragments that contribute to toxicity. Strategies that prevent this process thus hold therapeutic potential. Here we develop CRISPR base editors that generate proteolysis-resistant HTT isoforms by disrupting the splice acceptor of HTT exon 13, an exon that encodes critical proteolytic cleavage sites implicated in N-terminal fragment production. When delivered to the striatum of an HD rodent model, these editors reduced HTT fragment formation, decreased aggregation, improved functional deficits and attenuated brain atrophy. Collectively, these results demonstrate the potential of base editing and splice-site modulation to mitigate mutant HTT toxicity in HD.
small molecules
2026-09-30 | Estrogen and progesterone receptor signaling as candidate neuroendocrine modulators in Huntington's disease.
Huntington's disease (HD) is a genetically driven neurodegenerative disorder marked by progressive corticostriatal dysfunction, excitotoxicity, mitochondrial impairment, and neuroinflammation. Disease-modifying therapies remain limited, and the receptor-specific relevance of neuroendocrine signaling is poorly defined.This review evaluates estrogen receptor beta (ERβ), G-protein-coupled estrogen receptor 1 (GPER1), and progesterone-derived neurosteroids, particularly allopregnanolone, as candidate modulators of HD vulnerability. A structured search of PubMed, Web of Science, and Scopus covered studies published from January 1, 1990, through October 1, 2025, supplemented by manual reference screening. Evidence from patients and HD models is prioritized; mechanistic findings from other neurodegenerative and excitotoxic models are interpreted cautiously.We examine receptor-specific effects on glutamatergic signaling, mitochondrial bioenergetics, microglial activation, oxidative stress, and transcription, including potential disruption of estrogen-responsive pathways by mutant huntingtin. Sex differences, hypothalamic-pituitary-gonadal axis disturbances, and neurosteroid fluctuations are also considered.Finally, we assess SERMs, ERβ-selective agonists, and progesterone-based strategies as hypothesis-driven adjuncts-not established treatments-while addressing thromboembolic risk, endocrine contraindications, CNS penetration, receptor selectivity, and drug interactions. This synthesis identifies evidence gaps and proposes testable questions for early-phase translational research.
2026-09-30 | Lipid-based Nanocarriers for Neurodegenerative Disorders: Bridging Blood-brain Barrier Biology and Translational Drug Delivery.
Neurodegenerative disorders, including Alzheimer's, Parkinson's, Huntington's disease, and amyotrophic lateral sclerosis, remain difficult to treat because the Blood-brain Barrier (BBB) severely restricts therapeutic access to the central nervous system. This review evaluates BBB biology and the potential of lipid-based nanocarriers to improve brain-targeted drug delivery and facilitate clinical translation. A structured narrative review of peer-reviewed preclinical and clinical literature published between 2000 and 2025 was conducted using PubMed, Scopus, and Web of Science. Evidence concerning BBB structure and transport mechanisms, lipid-based nanocarrier design, physicochemical characteristics, drug-release behavior, computational modelling, therapeutic applications, and translational challenges was critically synthesized. Liposomes, nanoemulsions, solid lipid nanoparticles, nanostructured lipid carriers, and lipid-polymer hybrid nanoparticles demonstrated improved drug solubility, stability, controlled release, systemic circulation, and brain targeting. Preclinical evidence indicates enhanced brain bioavailability and therapeutic effects, including reductions in neuroinflammation, oxidative stress, and disease-associated pathological processes. However, clinical translation remains constrained by formulation complexity, scalability, long-term safety, and inconsistent clinical outcomes. Integration of BBB transport biology with surface functionalization, receptormediated targeting, formulation engineering, and computational modelling may enable more rational nanocarrier development. Nevertheless, standardized characterization, reproducible manufacturing, comprehensive safety evaluation, and stronger clinical validation are required to bridge the gap between promising preclinical findings and therapeutic implementation. Lipid-based nanocarriers represent promising platforms for overcoming biological and pharmacokinetic barriers in neurodegenerative disorders. Further optimization and rigorous translational validation are essential to establish their safety, reproducibility, and clinical effectiveness.
2026-09-27 | Uncovering hidden protein networks in Huntington's disease: implications for pathogenesis and therapy.
Huntington's Disease is a neurodegenerative disorder that progresses over time and can be passed down from parent to child. In uncontrolled motor activities, behavioural problems come into play, as well as progressive mental decline. The CAG triplet in the HTT gene found on chromosome 4 undergoes changes, leading to the production of a mutant protein called huntingtin, which consists of a bigger-than-normal polyglutamine tract that then undergoes misfolding and produces toxic oligomers and fibrillar deposits that can cause dysfunction in normal cell functioning and therefore in nerve cells as well. Although early research linked the pathophysiology of Huntington's disease primarily to mHTT aggregation, more recent research indicates broad protein-protein interaction networks that affect several cellular pathways. Systems biology approaches using tools such as STRING, BioGRID, and Cytoscape have provided evidence of interconnected networks that promote proteostasis, mitochondrial dynamics, energy metabolism, neuroinflammation, synaptic transmission, and transcriptional and epigenetic regulation. Important protein hubs, including HSP70, DRP1, NLRP3, and TFEB, act as central controls that bind those pathways. mHTT-mediated defect in the function of the ubiquitin-proteasome system promotes mitochondrial oxidative stress, which triggers the NLRP3 inflammasome, leading to synaptic dysfunction and specific loss of striatal medium spiny neurons. Investigations using various experimental techniques, which involve R6/2 and YAC128 mouse models, neurons derived from human iPS cells, and multi-omics studies, reveal that faulty neuroplasticity develops before the formation of visible protein aggregates. As for therapeutics targeting central components of neuronal networks, they have all demonstrated certain neuroprotective effects.
2026-09-25 | Restoring Aquaporin-4 alleviates molecular and motor phenotypes in zQ175 mouse model of Huntington disease
Huntington&'s disease (HD) is characterized by progressive accumulation of mutant huntingtin (mHTT), neurodegeneration and motor dysfunction. Increasing evidence implicates impaired glymphatic function and loss of perivascular aquaporin 4 (AQP4) polarization in HD, suggesting that defective brain waste clearance may contribute to disease pathogenesis. Whether restoration of AQP4&-mediated glymphatic transport can ameliorate HD pathology remains unknown. We tested whether genetic restoration of AQP4 improves glymphatic function and HD&-associated phenotypes in heterozygous zQ175 knock-in mice. At 2 months of age, premanifest zQ175 mice received a single retro-orbital injection of BBB-penetrant AAV9&-PHP.eB encoding the AQP4 (M1 isoform). Glymphatic transport was assessed by intracisternal injection of fluorescent BSA 647 and quantification of parenchymal influx and drainage to the deep cervical lymph nodes. Perivascular AQP4 localization, mHTT aggregation, gliosis, DARPP32 immunoreactivity, CSF neurofilament light chain (NfL) and total Tau, structural brain volumes by 11.7T MRI, and motor behavior were assessed longitudinally through 12 months of age. AAV9&-PHP.eB&-AQP4 produced widespread brain expression and restored perivascular AQP4 localization in the striatum and cortex of zQ175 mice. AQP4 overexpression significantly increased glymphatic tracer influx into brain parenchyma and BSA-647 drainage to the deep cervical lymph nodes. At 12 months, AQP4 restoration reduced CSF NfL and total Tau concentrations, mHTT aggregate number and mean aggregate size, and striatal Iba1 positive microglia and GFAP-positive astrocytes (P < 0.05). AQP4 overexpression also preserved striatal DARPP32 immunoreactivity and significantly attenuated striatal atrophy measured by MRI. Female zQ175 mice showed improved balance-beam performance and locomotor activity, while effects on motor performance in males did not reach statistical significance. AQP4 overexpression attenuated body-weight loss in both sexes. No detectable structural, behavioral or body-weight abnormalities were observed following sustained AQP4 overexpression in wild-type mice. In summary, restoration of AQP4 enhances glymphatic transport and is associated with reduced proteopathic, neuroinflammatory and neurodegenerative phenotypes in zQ175 HD mice. These findings provide proof-of-concept that impaired glymphatic function is a modifiable component of HD pathology and support AQP4&-mediated restoration of brain waste clearance pathways as a potential disease-modifying therapeutic strategy.
2026-09-25 | miR-196a reduces mutant Huntingtin aggregates by Rad23b-mediated degradation in Huntington's disease.
Huntington's disease (HD) is a neurodegenerative disorder caused by abnormal expansions of poly-glutamine repeats in the mutant Huntingtin (mHTT). The expanded proteins form pathological aggregates to disrupt neuronal functions during disease progression, suggesting the clearance of the aggregates is considered as a potential direction for development of therapy. Our previous studies have demonstrated one specific microRNA, miR-196a, downregulates mHTT aggregates and improves the pathological phenotypes in HD. However, the detailed mechanism remains unclear. Proteomic analyses and bioinformatic tools were used to identify putative miR-196a targets in HD, and the expression of one target gene, Rad23b, was manipulated in different HD models to assess its role in mHTT aggregates. Here, we identify Rad23b as a key target, and miR-196a directly downregulates Rad23b to reduce mHTT aggregates and toxicity. We also show Rad23b overexpression worsens mHTT pathology, while its knockdown or knockout diminishes aggregates, primarily through the ubiquitin-proteasome system (UPS). Moreover, Rad23b interacts with mHTT aggregates via its ubiquitin-binding domains, and promotes their ubiquitination; however, Rad23b disrupts the chymotrypsin-like activity of UPS, and contributes to mHTT accumulation. In transgenic mouse models in vivo, Rad23b increases mHTT aggregates and cell death in brains, and also worsens motor dysfunction in HD transgenic mice. These findings demonstrate that critical role of Rad23b in miR-196a-reduced pathological aggregates, and highly suggest downregulating Rad23b or disrupting its interaction with mHTT may offer novel strategies to mitigate mHTT aggregates to delay disease progression.
cell therapies
2026-09-04 | Extracellular vesicles in neurodegenerative diseases: A new frontier in diagnosis and therapy.
Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease are among the progressive disorders of the nervous system that are characterized by the gradual destruction of neurons, the accumulation of misfolded proteins, and the limited effective therapeutic options. In recent years, numerous lines of evidence have emphasized the important role of extracellular vesicles (EVs) in the formation and progression of these diseases. These vesicles are membrane-bound nanoscale structures that are secreted by almost all cell types and play a role in cell-cell communication through the transfer of molecules such as proteins, lipids, and nucleic acids. In neurodegenerative disorders, EVs can facilitate the transport and dissemination of disease-related proteins, including amyloid-β, tau, α-synuclein, mutant huntingtin, SOD1, and TDP-43, thus contributing to the spread of pathological processes in different parts of the nervous system. On the other hand, the ability of these vesicles to cross the blood-brain barrier and reflect molecular changes occurring in the central nervous system makes them valuable candidates for the development of minimally invasive biomarkers. This review reviews the biogenesis, classification, isolation methods, and molecular content of EVs, and analyzes their role in the pathogenesis, diagnosis, and treatment of the most important neurodegenerative diseases. Also, the importance of EV-associated proteins, RNAs, and lipids as emerging diagnostic biomarkers, as well as the therapeutic potential of natural and engineered vesicles as drug delivery systems and regulators of neuroinflammation and neurodegenerative processes, is discussed.
2026-08-29 | Mechanism and progress of deep brain stimulation in the treatment of neurological and psychiatric disorders.
Deep brain stimulation (DBS) is a reversible and adjustable neurostimulation technique, and has been established as a significant therapeutic modality in functional neurosurgery although its mechanisms are not yet fully understood. The primary indications for DBS include movement disorders such as Parkinson's disease (PD) and dystonia, essential tremor (ET), and Huntington's disease (HD). In recent years, its application has expanded to encompass the treatment of various other neurological and psychiatric conditions, including epilepsy, depression, obsessive-compulsive disorder (OCD), Alzheimer's disease (AD), and Tourette syndrome (TS), although the indications for DBS currently approved by the Food and Drug Administration (FDA) are PD, dystonia, ET, OCD, and epilepsy. In this review, we summarize the prevailing hypotheses regarding the mechanisms through which DBS ameliorates neurological and psychiatric disorders. We also describe the advancements in DBS for treating PD, dystonia, epilepsy, and other brain disorders. Furthermore, we outline the limitations associated with DBS treatment to date. Through this comprehensive analysis, we aim to enhance the understanding of DBS applications in neurological and psychiatric diseases and suggest potential avenues for technological advancement.
2026-08-08 | Gelatin methacryloyl hydrogel as a potential scaffold for cell transplantation for Huntington's disease.
Cell replacement therapy is a promising strategy for treating Huntington's disease. Advances in cell reprogramming now allow the generation of clinically relevant cells; however, conventional delivery methods can compromise long-term cell survival and maturation. Hydrogels have emerged as supportive three-dimensional scaffolds that better mimic the in vivo environment. This study examined whether encapsulating human-induced lateral ganglionic eminence precursor cells (hiLGEPs) in gelatin methacryloyl (GelMA) hydrogel enhanced differentiation after transplantation into the striatum of the quinolinic acid lesion rat model of Huntington's disease. hiLGEPs were delivered either in cell culture medium (n = 5) or in a pre-crosslinked GelMA solution (n = 4) prior to transplantation. GelMA was polymerized in situ using a visible-light optical fibre system, and grafts were assessed 4 weeks later. Transplanted cells survived in all animals. Notably, GelMA-encapsulated hiLGEPs produced significantly more protein gene product 9.5 (PGP9.5+) neurons than those delivered in cell culture medium. Transplanted cells in both groups differentiated into microtubule-associated protein 2 (MAP2+) and GABA+ phenotypes, with no detectable differences in graft volume. These findings provide the first evidence that encapsulating hiLGEPs in GelMA enhances early neuronal differentiation following transplantation, supporting GelMA hydrogel as a promising delivery scaffold for cell replacement therapy in Huntington's disease.
2026-06-26 | Oxidative stress and molecular chaperones: a dynamic crosstalk in neurodegenerative disorders.
Neurodegenerative diseases (NDs), such as Alzheimer's disease, Parkinson's disease, and Huntington's disease are discussed as representative examples of conditions in which oxidative stress and proteostasis imbalance contribute to progressive neuronal dysfunction. Oxidative stress, defined as an imbalance between reactive oxygen species (ROS) production and antioxidant defenses, is widely recognized as a key contributor to ND pathogenesis. Excessive ROS disrupt cellular homeostasis and promotes protein misfolding and aggregation, thereby compromising the proteostasis network. In response to this stress, molecular chaperones, including members of heat shock protein (Hsp) family, play a crucial protective role by maintaining protein folding integrity and preventing toxic aggregation. Furthermore, mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) serve as carriers of bioactive molecules, including antioxidants and molecular chaperones, offering a unique mechanism to restore cellular homeostasis. This review explores the interplay between oxidative stress and molecular chaperones in the pathogenesis of NDs and highlights the emerging therapeutic potential of MSC-EVs as modulators of oxidative and proteostatic imbalance.
2026-06-18 | Sequential Clinical Changes Following Autologous Mesenchymal Stem Cell Therapy in a Patient With Concurrent Huntington's Disease and Ankylosing Spondylitis: A Case Report.
Huntington's disease (HD) and ankylosing spondylitis (AS) are genetically and pathophysiologically distinct conditions, and their concurrent management may present a complex clinical challenge. A case is reported of a 35-year-old man with genetically confirmed HD and concurrently diagnosed AS, treated with autologous mesenchymal stem cell (MSC) therapy over three consecutive monthly sessions (50 million MSCs per session, total 150 million administered, intravenous and epidural routes). Validated disease-specific assessments were performed at each visit by the treating neurologist before the cell administration of that day: the Unified Huntington's Disease Rating Scale motor score (UHDRS motor), the Bath Ankylosing Spondylitis Functional Index (BASFI), and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Three serial assessments captured changes from baseline (cumulative dose 0) through cumulative doses of 50 million and 100 million MSCs, after which the third (final) dose was administered without subsequent reassessment. Over the two-month observation period, UHDRS motor score declined from 19 to 2, BASFI from 4.0 to 1.0 (with a transient increase to 8.5 at the second visit), and BASDAI from 2.0 to 1.0. No serious short-term adverse events were observed during the active treatment period. Given the single-patient design, concurrent pharmacotherapy, unblinded assessment, absence of objective biomarkers, and absence of post-third-dose assessment, causal attribution to MSC therapy cannot be established. The observation is presented as hypothesis-generating and warrants further investigation under controlled conditions.
proteins
2026-09-28 | Masking phosphatidylserine prevents neuronal loss in two distinct Drosophila models of neurodegeneration.
Neuronal loss is a hallmark of neurodegenerative diseases. Phosphatidylserine (PS), a key "eat me" signal, is exposed on stressed viable neurons, triggering their premature phagocytosis by activated glia. We investigated whether PS masking could serve as a universal strategy to prevent neuronal loss in two distinct Drosophila models of neurodegeneration: an adult-stage-specific knockdown of skpA and a Huntington's disease model initiated during embryogenesis. Both models exhibit neuronal loss, motor dysfunction, and reduced lifespan. To mask PS, we used a truncated form of Milk Fat Globule-Epidermal Growth Factor 8, a glycoprotein that binds PS without promoting engulfment. PS masking preserved two neuronal populations in both models, indicating that these neurons were eliminated alive via phagoptosis. Motor function and lifespan were improved to varying degrees, depending on the timing and severity of neuronal damage. These findings reveal that aberrant glial phagocytosis contributes to neuronal vulnerability and identify PS masking as a promising therapeutic approach for neurodegenerative diseases.
2026-09-24 | Protecting Against Cytoplasmic Protein Aggregates With Cytoplasmic PML Variants.
Cytoplasmic protein aggregation is a defining feature of multiple neurodegenerative diseases, including amyotrophic lateral sclerosis, frontotemporal dementia, Huntington's disease, and certain forms of motor neuron disease. Recent evidence indicates that promyelocytic leukemia protein (PML) and engineered PML-derived variants can act as versatile aggregate-remodeling factors. In particular, cytoplasmically redirected PML variants recognize pathological cytoplasmic inclusions and promote their clearance. Here, we describe a protocol to generate and validate two engineered cytoplasmic PML variants: full-length mPML, which is redirected to the cytoplasm by disruption of its nuclear localization sequence, and the truncated mPMLΔRBC variant, which lacks the RING, B-box, and coiled-coil domain but retains aggregate-reducing activity. The protocol integrates fluorescence-based imaging, bimolecular fluorescence complementation, detergent-soluble/insoluble fractionation, and validation in primary rat cortical neurons. This workflow provides a practical platform for assessing cytoplasmic aggregate burden and for comparing the aggregate-remodeling activities of PML-derived constructs. It can also be adapted to other disease-associated aggregation-prone proteins, including TDP-43, SOD1, FUS, tau, polyGA, and polyQ-expanded proteins. Key features • Describes the generation and validation of two complementary cytoplasmic PML variants: full-length mPML and truncated mPMLΔRBC. • Provides fluorescence-based and BiFC-based assays to visualize pathological cytoplasmic protein assemblies. • Includes detergent-soluble/insoluble fractionation for biochemical assessment of aggregate burden. • Establishes a primary rat cortical neuron workflow to evaluate the effect of mPML on TDP-43-CTF aggregates. • Can be adapted to other aggregation-prone proteins and additional PML-derived aggregate-remodeling candidates.
2026-09-04 | Targeting Klotho Signaling for Neuroprotection in Huntington's Disease: A Comprehensive Review.
HD is a hereditary neurodegenerative disease caused by the amplification of the CAG trinucleotide repeat in the HTT gene, leading to a Mutant Huntingtin (mHTT) protein that dysregulates transcription, promotes protein aggregation, induces neuroinflammation, and impairs mitochondrial function. Motor dysfunction, cognitive decline, and mental disorders are manifestations of these biochemical abnormalities. Effective disease-modifying treatments are still limited, even with recent improvements. This review investigates the increasing relevance of Klotho, an anti-aging protein with neuroprotective, antioxidant, and anti-inflammatory characteristics, as a possible therapeutic target in Huntington disease. We did a comprehensive literature search across PubMed, Scopus, and Web of Science databases. Klotho's molecular functions in neural protection, energy metabolism, oxidative stress reduction, and anti-inflammatory signalling were investigated in the context of HD pathogenesis. Klotho appears to influence critical neurodegenerative processes involved in HD. It inhibits NF-κB and NLRP3 inflammasome activity, stimulates antioxidant enzyme expression (SOD, catalase), promotes GluN2B-NMDA receptor-mediated synaptic plasticity, and increases astrocytic aerobic glycolysis via FGFR1-ERK signaling. These functions may mitigate mHTT- induced neuronal damage. Pharmacologic treatments (e.g., PPAR-γ agonists), vitamin D, and lifestyle interventions can all modulate klotho expression. Klotho exhibits neuroprotective effects in Huntington's disease by reducing NF-κB/NLRP3- mediated inflammation, strengthening antioxidant defenses, promoting GluN2B-NMDA- dependent synaptic plasticity, and improving astrocytic metabolic support via FGFR1-ERK signaling. One intriguing treatment approach for mutant huntingtin-induced neurotoxicity is the modification of klotho expression. Klotho is a promising neurochemical modulator with disease-modifying properties in HD. Its multifunctional protective activities are consistent with important pathological markers of HD, necessitating more preclinical and clinical studies to confirm its translational value.
2026-08-11 | A Novel Plate Reader-Based Protocol for Measurement of DNAJB6 Dimerization Activity.
Progressive neurodegeneration linked to the accumulation of misfolded proteins is a hallmark of several neurodegenerative disorders, including Parkinson's disease, Huntington's disease, and Alzheimer's disease. Dysfunction in the protein homeostasis machinery correlates with pathology. The chaperone protein DNAJB6 is expressed in neurons and oligodendrocytes and has been shown to play a key role in preventing amyloid aggregation by binding to amyloidogenic proteins and facilitating their refolding or degradation, in cooperation with other chaperones. Here, we describe a simple and feasible assay that enables high-throughput screening for DNAJB6 activity in a plate reader format. We use genetically engineered HEK293 cells that stably express DNAJB6 fused to either CFP or YFP. These cells can be plated into multi-well plates, and the fluorescence resonance energy transfer (FRET) signal can be measured for analysis of DNAJB6 dimerization, which is linked to DNAJB6 activity. The protocol can be used for drug screening and to identify compounds that increase DNAJB6 dimerization, and can serve as a starting point for finding new medicines that act through modulating DNAJB6 activity. Key features • The protocol requires a plate reader capable of FRET analysis and bandwidth adjustment for CFP/YFP separation. It was developed using a CLARIOstar plate reader. • The protocol requires access to the authors' FRET DNAJB6 cell line or equivalent cells with stable expression of CFP/YFP-DNAJB6. • The assay measures DNAJB6 dimerization and can potentially be adapted to other proteins whose functional state is linked to dimerization activity. • The protocol is useful for compound screening purposes and requires pre-existing knowledge of basic cell culture.
2026-08-05 | Targeting mitochondria for the treatment of neurodegenerative diseases.
Mitochondria are central regulators of cellular metabolism, redox balance, calcium signaling, and cell survival, making them essential for neuronal function. Because neurons rely heavily on mitochondrial oxidative phosphorylation to meet their high energetic demands, mitochondrial dysfunction has emerged as a key pathogenic driver in major neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Defects in mitochondrial bioenergetics, excessive reactive oxygen species production, impaired mitochondrial dynamics, disrupted mitophagy, and dysregulated calcium handling collectively contribute to neuronal damage, synaptic dysfunction, and neuroinflammation. These insights have prompted growing interest in therapeutic strategies that directly target mitochondria to restore organelle homeostasis. Recent advances in chemical biology and nanomedicine have enabled the development of mitochondria-targeted ligands, peptide-based targeting systems, and carrier or nanotechnology-enabled delivery platforms designed to overcome biological barriers and selectively deliver therapeutic cargos to mitochondria within the central nervous system. In this Review, we summarize mitochondrial pathological mechanisms in neurodegenerative diseases and discuss emerging mitochondria-targeted therapeutic strategies, highlighting delivery technologies, therapeutic modalities, and translational challenges. Although most strategies remain at the preclinical or proof-of-principle stage, these advances are beginning to shape a conceptual framework for precision mitochondrial medicine, with the longer-term goal of developing disease-modifying interventions for neurodegenerative disorders.
oligonucleotides
2026-09-05 | New directions in diagnosis and therapeutic for Huntington disease
Physical sign, behavioral, as well as increasing cognition are hallmarks of Huntington Disease (HD), a monogenic neurodegenerative illness that causes early impairment and death. In 1993, the genetic effect was identified as an enlarged Cytosine, Adenine, Guanine repeat on chromosome 4's exon 1 of the Huntington gene. The assessment of individuals who are clinically afflicted by Huntington's disease depends on the differential diagnosis. A variety of treatments are accessible to lessen the symptoms of Hunti ngton's disorder, and efficient solutions for its chorea. Additionally, RNA interference medicines are being developed for clinical use, antibody treatments, stem cell treatments, etc. Discussing the effectiveness of the recent therapy for Huntington's illness is the main ambition in this regard comprehen sive analysis.
2026-08-12 | Blocking somatic repeat expansion and lowering huntingtin by RNAi synergize to attenuate Huntington's disease pathogenesis in mice.
Huntington's disease (HD) is a progressive neurodegenerative disorder with no approved therapies. Despite multiple clinical trials, huntingtin (HTT)-lowering strategies have yet to show meaningful clinical benefit. Both somatic expansion and toxic HTT species are key molecular drivers of HD, yet therapeutic strategies targeting these pathways have never been directly compared or evaluated in combination. Using therapeutic divalent siRNAs, we assessed the long-term impact of silencing MutS homolog 3 (MSH3), a critical regulator of somatic expansion, HTT, or both in Q111 HD mice (>110 CAGs), which develop robust expansion, mutant HTT inclusions, and transcriptional dysregulation by 12 months. Long-term MSH3 silencing blocked somatic expansion, reduced inclusions, and normalized gene expression. HTT silencing alone had a limited effect, whereas combined MSH3/HTT targeting synergistically eliminated inclusions and restored transcriptomic profiles. Parallel treatment in wild-type mice showed no toxicity, supporting the safety of long-term intervention. These findings position somatic expansion as a promising therapeutic target and demonstrate the potential of RNAi-based cosilencing of MSH3 and HTT as a disease-modifying strategy for HD.
2026-08-11 | Emerging Pharmacological Therapies for Huntington's Disease: Translational Insights from Recent Clinical Trials.
Huntington's disease [HD] is a progressive, autosomal dominant neurodegenerative disorder caused by a pathogenic CAG repeat expansion in the HTT gene, resulting in mutant huntingtin [mHTT] protein accumulation, neuronal dysfunction, and selective neurodegeneration. Current pharmacological management remains largely symptomatic, with no approved therapies capable of modifying disease progression. In recent years, however, significant advances in molecular neuroscience and translational medicine have accelerated the development of disease-modifying strategies targeting the underlying pathogenic mechanisms of HD. This review synthesizes emerging pharmacological therapies with a particular focus on insights derived from recent and ongoing clinical trials. Key therapeutic approaches discussed include gene-silencing technologies such as antisense oligonucleotides, RNA interference, and CRISPRCas9- based strategies, as well as small-molecule modulators targeting mutant huntingtin aggregation, proteostasis, autophagy, mitochondrial dysfunction, and neuroinflammation. In addition, advances in symptomatic treatments addressing motor, cognitive, and psychiatric manifestations are reviewed. The article critically examines translational challenges encountered in clinical development, including blood-brain barrier penetration, allele selectivity, dosing paradigms, patient heterogeneity, biomarker integration, and ethical considerations associated with irreversible genetic interventions. Lessons learned from both successful and failed trials highlight the importance of precision medicine approaches, biomarker-guided trial designs, and combination therapies targeting multiple pathogenic pathways. Collectively, this review provides an updated and clinically relevant overview of the evolving HD therapeutic landscape and outlines key considerations for translating molecular advances into effective and safe pharmacological interventions.
2026-07-08 | Huntington's disease in the era of somatic instability, biomarkers, and targeted therapies: A narrative review.
Huntington's disease (HD) is a progressive, autosomal dominant neurodegenerative disorder caused by cytosine-adenine-guanine (CAG) trinucleotide repeat expansion in the huntingtin gene (HTT), resulting in mutant huntingtin (mHTT) with toxic gain-of-function and partial loss of normal huntingtin function. This narrative review summarizes recent advances in genetics, pathophysiology, clinical features, diagnostic assessment, biomarkers, and therapeutic development. Genetic testing demonstrating an expanded HTT CAG repeat is the definitive diagnostic test and should be interpreted with genetic counseling and attention to allele categories. Pathophysiologically, HD involves CAG instability, age-dependent somatic expansion in vulnerable neurons, transcriptional dysregulation, proteostasis failure, mitochondrial dysfunction, excitotoxicity, and neuroinflammation, leading primarily to degeneration of striatal medium spiny neurons and later cortical involvement. Clinically, HD can begin from juvenile to late-adult life and manifests with motor, cognitive, psychiatric, and behavioral symptoms that evolve from premanifest biological change to functional decline. Current clinical care relies on symptom-directed treatment, whereas quantitative neuroimaging, cerebrospinal fluid biomarkers are mainly used for research and trial enrichment. Symptomatic management includes vesicular monoamine transporter type 2 inhibitors, antipsychotics, rehabilitation, nutritional support, and multidisciplinary care. Emerging disease-modifying approaches include HTT-lowering, somatic expansion inhibition, and gene-based therapies, but efficacy depends on target selectivity, timing, delivery route, dose, and patient selection.
2026-07-03 | Mismatch repair dissection by in vivo RNAi reveals dose-dependent modulators of somatic instability and proteome remodeling in Huntington's disease.
Human and mouse genetics have established mismatch repair (MMR) as a central mediator of somatic repeat expansion, a key pathogenic process in Huntington's disease (HD) and related disorders. How individual MMR components function within the intact mammalian brain and interact with broader cellular networks remains poorly understood. We screened more than 500 chemically stabilized siRNAs targeting 10 MMR genes and used interventional RNAi in the Q111 HD mouse model to systematically dissect MMR function in vivo. MSH3 and PMS1 emerged as the most dose-sensitive regulators of somatic expansion but displayed markedly different effects on proteome stability. Quantitative proteomics generated an in vivo atlas of MMR component abundance and cross-regulation in the mammalian CNS, uncovering extensive connectivity between DNA repair, transcriptional regulation, chromatin remodeling, and mitochondrial biology. Together, these findings establish a systems-level framework linking MMR biology to neuronal function and offer mechanistic insight into selective neuronal vulnerability in HD.
other
2026-09-27 | Huntingtin Aggregate-Responsive Autophagy Gene Circuit Mitigates Disease Pathology in R6/2 Mice.
The accumulation of mutant huntingtin (mHTT) aggregates drives the pathology of Huntington's disease (HD), yet therapies capable of distinguishing toxic species from wild-type proteins remain elusive. Here, a synthetic gene circuit, termed ARAA, was engineered to couple the preferential recognition of aggregated polyQ species to the on-demand activation of autophagy. Utilizing a repurposed bacterial NarX-NarL system fused with a conformation-sensitive intrabody, the circuit detects pathological polyQ conformers and triggers the transcriptional expression of the master autophagy regulator TFEB. To enable systemic application, the ARAA plasmid is encapsulated in CD98-targeted immunoliposomes (LIP-CD98) that facilitate efficient blood-brain barrier crossing via receptor-mediated transcytosis. In the R6/2 HD mouse model, ARAA treatment significantly reduces mHTT burden, attenuates neuroinflammation, and rescues synaptic deficits. This closed-loop intervention improves motor function and extends lifespan. Together, these findings provide proof-of-concept evidence that aggregate-responsive regulation of autophagy can mitigate disease-associated phenotypes in exon 1-based HD models.
2026-09-24 | Chemically modified CRISPR enzymes for multi-organ genome editing in vivo.
Delivery remains the main obstacle to the development of in vivo genome editing therapies. CRISPR ribonucleoproteins confer high editing activity with transient exposure but lack intrinsic cell entry and targeting. Here we introduce PERCEPT, a delivery platform featuring reversible, covalent modification of CRISPR enzymes. PERCEPT enables modular installation of shielding polymers, amphiphilic delivery peptides and targeting ligands, allowing traceless cytosolic release of the native editor. A formulation incorporating an amphiphilic delivery peptide and the neuron-targeting ligand TET1 edited approximately 56% of striatal volume and 78% of neurons within edited regions after local striatal administration. In the R6/2 Huntington's disease model, PERCEPT mediated targeted editing of the mutant human HTT transgene, reducing mutant huntingtin aggregate burden and shifting local transcriptional programs away from inflammatory and injury-associated states. Tissue-adapted formulations edited 53% of Müller glia following intravitreal delivery, increased skeletal muscle reporter fluorescence tenfold versus unconjugated control following intramuscular injection, and enabled lung airway epithelial cell that persisted for three months following intranasal delivery. Rapid screening revealed that local anatomical and cellular barriers require distinct surface display for optimal editing. These results establish reversible chemical modification as a general strategy for adapting CRISPR enzyme delivery across multiple target tissues in vivo.
2026-08-23 | Comparative Analysis of CRISPR-Cas9 and Gene-Lowering Approaches for the Treatment of Huntington’s Disease
Huntington's disease is a severe autosomal dominant inherited disease, which means a person will suffer from this disease even if only one allele is mutated.The disease is caused by CAG trinucleotide repeat expansion in 4th chromosome, HTT gene, and only a little approach could be helpful to treat this disease from now.Today, approximately 5 out of every 100,000 people will suffer from this disease all around the world.This article explores two groundbreaking technologies that emerged at the end of 2025, marking the first time Huntington's disease has ever been successfully treated.Two rivaling approaches are at play: CRISPR-Cas9 editing of the gene responsible for Huntington's disease (HTT), and gene-lowering, which involves the degradation of the mRNA produced by miRNA.In previous research, the gene-lowering method functioned in mutant Huntington mRNA, instead of targeting the gene itself.This paper compares the benefits and shortcomings of these two prevailing methods for curing Huntington's disease.According to this paper, the gene-lowering method is relatively mature, and it is getting increasingly closer to being released in the market as a drug.The CRISPR-Cas 9 method is theoretically more efficient due to its once-and-for-all characteristic, and could be more convenient.However, both treatments are all facing the delivery challenge.This paper provides a comprehensive comparison of two novel approaches for treating Huntington's disease, providing a roadmap for where this research needs improvement, and may progress in the future.
2026-08-04 | Enhancing the detection of HTT1a with neoepitope antibodies in mouse models of Huntington's disease.
Huntington's disease is an inherited neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of the huntingtin (HTT) gene, encoding an expanded polyglutamine tract in the huntingtin (HTT) protein. The pathogenic CAG repeat of HTT is unstable and undergoes progressive somatic expansion in specific brain cells and peripheral tissues throughout life. Genes involved in DNA mismatch repair pathways, which promote repeat expansion, have been identified as genetic modifiers of the disease. Consequently, the rate of CAG repeat expansion is a key determinant driving the age of onset and disease progression. As the CAG repeat expands, alternative processing of HTT pre-mRNA increasingly favours production of the HTT1a transcript, which encodes the highly pathogenic and aggregation-prone HTT1a protein. This process provides a mechanistic link between CAG repeat expansion and disease pathogenesis, as increased HTT1a production accelerates HTT aggregation and neuronal dysfunction. HTT1a has previously been detected in Huntington's disease mouse models by using immunoprecipitation coupled with western blotting, homogeneous time-resolved fluorescence (HTRF) and Meso Scale Discovery (MSD) bioassays and immunohistochemistry. These approaches were developed using MW8, a neoepitope antibody that specifically recognizes the C-terminus of HTT1a. MW8 is a relatively weak antibody with limited detection sensitivity. To generate more robust HTT1a-specific reagents, two novel recombinant antibodies, 1B12 and 11G2, have been developed for evaluation. Using an allelic series of knock-in (HdhQ20, HdhQ50, HdhQ80, HdhQ111, CAG140 and zQ175) mice, alongside transgenic YAC128 and N171-82Q models, we extensively evaluated and compared the performance of MW8, 1B12 and 11G2. We demonstrate that 1B12 and 11G2 function as HTT1a-specific neoepitope antibodies by immunoprecipitation with western blotting and by immunohistochemistry. To enhance HTT1a detection using HTRF and MSD technology platforms, we further evaluated the performance of 1B12 and 11G2 in HTT bioassays using cortical lysates from zQ175 and YAC128 mice. In zQ175 mice, enhanced detection of aggregated HTT1a by HTRF and MSD revealed that HTT fragments longer than HTT1a can be incorporated into HTT1a-containing aggregates. The most sensitive assays were subsequently applied across the allelic series of knock-in mice to assess the effect of polyglutamine length on bioassay performance. For optimal sensitivity, we recommend the preferential use of 1B12 for HTRF assays and 11G2 for MSD assays. Collectively, these findings establish 1B12 and 11G2 as robust antibodies to reliably detect and track HTT1a pathology in vivo and promote the replacement of previously used MW8-based experimental approaches.
2026-07-30 | In vivo CRISPR base editing for treatment of Huntington's disease.
Huntington's disease (HD) is a fatal neurodegenerative disorder caused by an expanded CAG repeat within exon 1 of the huntingtin (HTT) gene, resulting in a mutant protein that drives neuronal dysfunction and loss. A key event in the pathogenesis of HD is proteolytic cleavage of mutant HTT, which generates aggregation-prone N-terminal fragments that contribute to toxicity. Strategies that prevent this process thus hold therapeutic potential. Here we develop CRISPR base editors that generate proteolysis-resistant HTT isoforms by disrupting the splice acceptor of HTT exon 13, an exon that encodes critical proteolytic cleavage sites implicated in N-terminal fragment production. When delivered to the striatum of an HD rodent model, these editors reduced HTT fragment formation, decreased aggregation, improved functional deficits and attenuated brain atrophy. Collectively, these results demonstrate the potential of base editing and splice-site modulation to mitigate mutant HTT toxicity in HD.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
78 orphan drug designations for Huntington disease, including 3 approved therapies.
78 orphan drug designations for Huntington disease, including 3 approved therapies.
Drug | Therapy type | Orphan designation | Clinical trial status | Sponsor |
|---|---|---|---|---|
21-amino acid peptide targeting expanded CAG repeat RNA | peptides | FDA | — | Rare Power Limited |
sulphamic acid, 6,7,8,9,10,11-hexahydro-6-oxobenzo[b]cyclohepta[d]pyran-3-yl ester | small molecules | FDA | — | Olavide Neuron STX S.L. |
a small molecule agonist of TrkB receptor | small molecules | FDA | — | Shaanxi Micot Technology Co., Ltd. |
tiapride | small molecules | FDA | — | ArKri Therapeutics |
Bevantolol hydrochloride | small molecules | EMA | Som Innovation Biotech S.A. | |
monosialotetrahexosylganglioside sodium salt of porcine brain origin (pGM1) | other | FDA | — | Zulia Biotech Inc. |
Votoplam | small molecules | EMA | Novartis Europharm Limited | |
2'-O-(2-methoxyethyl) and 2¿-O-methyl modified antisense oligonucleotide targeted to mutant huntingtin RNA | oligonucleotides | FDA | Wave Life Sciences USA, Inc. | |
votoplam | small molecules | FDA | Novartis Pharmaceuticals Corporation | |
(3beta,24S)-25,25,25-trifluoro-3-methyl-26,27-dinorergost-5-ene-3,24-diol | small molecules | FDA | Sage Therapeutics | |
Virus-like particle containing Cas9/gRNA ribonucleoprotein targeting the human HTT gene | gene therapies | FDA | — | Shanghai BDgene Co., Ltd. |
Virus-like particle containing Cas9/gRNA ribonucleoprotein targeting the human HTT gene | gene editing enzymes | EMA | — | Laura Nae |
A plasmid encoding a rabies virus glycoprotein tag & lysosome-associated membrane glycoprotein 2 fusion protein gene and a mutant huntingtin small interfering RNA | combination | FDA | ExoRNA Bioscience Nanjing Co. Ltd. | |
Dalzanemdor | small molecules | EMA | Raremoon Consulting Esp S.L. | |
valbenazine [Ingrezza] | small molecules | FDA | Approved | Neurocrine Biosciences Inc. |
synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin protein | peptides | FDA | — | centre national de la recherche scientifique |
humanized recombinant immunoglobulin G (IgG) 4 monoclonal antibody against C1q | antibodies | FDA | Annexon, Inc. | |
an antisense oligonucleotide that has been developed to target expanded CAG repeats in messenger ribonucleic acid (mRNA) | oligonucleotides | FDA | Vico Therapeutics B.V. | |
Bevantolol Hydrochloride (HCl) | small molecules | FDA | SOM Innovation Biotech S.A. | |
Branaplam | small molecules | FDA | Novartis Pharmaceuticals Corporation | |
fasudil HCL | small molecules | FDA | — | Woolsey Pharmaceuticals, Inc. |
Umbilical Cord Mesenchymal Stem Cells | cell therapies | FDA | — | Acen Regenerative Medicine Sci-Tech Co., Ltd. |
2-(3,7-dimethyl-octa-2, 6-dienyl)-6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone | small molecules | EMA | — | Emerald Health Pharmaceuticals España, S.L. |
vasopressin 1a receptor antagonist | small molecules | FDA | Azevan Pharmaceuticals, Inc. | |
glycerol tribenzoate | small molecules | FDA | — | Forest Hills Partners Hong Kong Limited |
(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione OR [(1E,4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one] | small molecules | FDA | — | AnnJi Pharmaceutical Co. Ltd. |
ADENO-ASSOCIATED VIRAL VECTOR SEROTYPE RH10 CONTAINING THE HUMAN CHOLESTEROL 24-HYDROXYLASE GENE | gene therapies | EMA | AskBio France | |
recombinant adeno-associated virus, serotype 1, containing a transgene that encodes a microRNA targeting huntingtin messenger RNA | gene therapies | FDA | Voyager Therapeutics | |
2,4-dinitrophenol | small molecules | FDA | — | Mitochon Pharmaceuticals, Inc. |
delta-9-tetrahydrocannabinol and cannabidiol | small molecules | FDA | MMJ International Holdings | |
(+)-alpha-dihydrotetrabenazine | small molecules | FDA | — | Adeptio Pharmaceuticals, Ltd |
recombinant adeno-associated virus vector containing DNA encoding INT41 intrabody | gene therapies | FDA | — | Vybion Inc. |
monosialotetrahexosylganglioside | small molecules | FDA | — | Qilu Pharmaceutical Co., Ltd. |
2-(3,7-Dimethyl-octa-2, 6-dienyl)¿6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone | small molecules | FDA | — | Emerald Health Pharmaceuticals Inc. |
Adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene | gene therapies | EMA | uniQure Biopharma B.V. | |
adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene | gene therapies | FDA | uniQure Biopharma B.V. | |
synthetic stereopure antisense oligonucleotide specific to the mutant huntingtin mRNA transcript at the U variant of single nucleotide polymorphism rs326331 | oligonucleotides | FDA | Wave Life Sciences Ltd. | |
laquinimod sodium | small molecules | FDA | Active Biotech AB | |
Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Gly-Gly-Asp-Leu-Leu-Pro-Arg-Gly-Ser | peptides | EMA | — | Granzer Regulatory Consulting & Services GmbH |
humanized IgG4 monoclonal antibody that binds to the SEMA4D antigen | antibodies | FDA | Vaccinex, Inc. | |
Mardepodect [PF-02545920] | small molecules | EMA | Pfizer Limited | |
antisense oligonucleotide targeting the U isoform of SNP rs362307 | oligonucleotides | FDA | Wave LIfe Sciences | |
Tominersen | oligonucleotides | FDA | Genentech, Inc. | |
5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline | small molecules | EMA | [INACTIVE] Veristat Spain S.L. | |
AASSGVSTPGSAGHDIITEQPRS | peptides | EMA | — | Centre National de la Recherche Scientifique (CNRS) |
4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-ditert-butylphenol hydrochloride [BN82451B] | small molecules | EMA | Ipsen Pharma | |
Chimeric 2'-O-(2-methoxyethyl) modified oligonucleotide targeted to huntingtin RNA | oligonucleotides | EMA | Roche Registration GmbH | |
phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis (1,1-dimethyethyl) monohydrochloride | small molecules | FDA | Ipsen Biopharmaceuticals, Inc. | |
2'-O-methyl phosphorothioate RNA oligonucleotide, 5'-m5CUGm5CUGm5CUGm5CUGm5CUGm5CUGm5CUG-3' | oligonucleotides | EMA | Vico Therapeutics B.V. | |
5-bromo-N-(prop-2-yn-1-yl)-2-(1H-1,2,4-triazol-1-yl)pyrimidine-4,6-diamine | small molecules | EMA | Palobiofarma S.L. | |
d6-tetrabenazine, deutetrabenazine [Austedo] | small molecules | FDA | Approved | Teva Branded Pharmaceutical Products R&D, Inc. |
5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride | small molecules | FDA | Prana Biotechnology Limited | |
Cysteamine bitartrate | small molecules | EMA | Chiesi Farmaceutici S.p.A. | |
carbenoxolone | small molecules | FDA | — | Oxalys Pharmaceuticals, Inc. |
2-[4-(1-Methyl-4-pyridin-4-yl-lH-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid | small molecules | FDA | Pfizer Inc. | |
small molecule inhibitor of phosphodiesterase 10 | small molecules | FDA | Omeros Corporation | |
lithium citrate tetrahydrate (in reverse micelle formulation) | small molecules | FDA | — | Medesis Pharma |
Lithium citrate tetrahydrate (in reverse-micelle formulation) | small molecules | EMA | — | Medesis Pharma |
selisistat | small molecules | FDA | AOP Orphan Pharmaceuticals AG | |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide | small molecules | EMA | Aop Orphan Pharmaceuticals GmbH | |
recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) | gene therapies | FDA | — | Neurologix, Inc. |
dimebon | small molecules | FDA | Medivation, Inc. | |
Latrepirdine dihydrochloride | small molecules | EMA | IDEA Innovative Drug European Associates Limited | |
cysteamine | small molecules | FDA | Horizon Therapeutics USA, Inc. | |
Clotrimazole | small molecules | FDA | — | EnVivo Pharmaceuticals, Inc. |
4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl | small molecules | FDA | Prilenia Therapeutics | |
Creatine | small molecules | FDA | Marathon Pharmaceuticals, LLC | |
4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine x HCl | small molecules | EMA | Ferrer Internacional S.A. | |
ubiquinol | small molecules | FDA | Gel-Tec, Division of Tishcon Corp. | |
Coenzyme Q10 | small molecules | FDA | Integrative Therapeutics, Inc. | |
Ethyl Eicosopentaenoate | small molecules | EMA | Amarin Neuroscience Limited | |
Ethyl eicosapentaenoate | small molecules | FDA | Laxdale Ltd. | |
Remacemide | small molecules | FDA | — | AstraZeneca LP |
Tiapride | — | FDA | — | Sanofi-Synthelabo, Inc. |
Tetrabenazine [Xenazine] | small molecules | FDA | Approved | Prestwick Pharmaceuticals, Inc |
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease. | cell therapies | FDA | — | Diacrin/Genzyme LLC |
Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation | cell therapies | FDA | — | Diacrin/Genzyme LLC |
Riluzole | small molecules | FDA | Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
“Terminated” – programs with discontinued clinical trials, or with no updates reported for 5 years after completion or 12 years after the last trial started.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.